What is important to notice is that Insiders control 53% and going private is a possibility.The Bakers are M&A artists but maybe they'll make an exception in this case since the genomic market is expected to grow to 25 B
For $3850 a test the insurance companies will soon make it mandatory. The market is just getting started. Prostate is off ramp much more quickly than Breast and colon because of the unnecessary spending
There was no "offering". There was simply an update on the original that was set to expire July 13.
3 4 ?5 times? current price? The longer the company can hold out.
Prostate diagnostic is larger than breast cancer and colon cancer in the number of unnecessary surgeries COMBINED. The AAPL of genomic innovation. Stock is cheap
8:01AM Genomic Health announces publication of second positive validation of oncotype DX colon cancer test confirming its value beyond conventional markers (GHDX) 28.85 : Co announced that the Journal of Clinical Oncology (JCO) published positive results from the large CALGB 9581 clinical validation study of the Oncotype DX? colon cancer test in stage II colon cancer patients. The findings provide further confirmation that the Oncotype DX Recurrence Score (RS) results improve the ability to differentiate high recurrence risk disease from low, beyond conventional factors such as T-stage, mismatch repair (MMR) status, nodes examined, grade and lymphovascular invasion.